Immutep TACTI-002 eftilagimod alpha pembrolizumab NSCLC Phase II 2022

Phase II trial results from TACTI-002 demonstrating eftilagimod alpha (soluble LAG-3) combined with pembrolizumab in first-line non-small cell lung cancer. The study shows an ORR of 40.4% in a PD-L1 unselected population with deep, durable responses and a median duration of response of 21.6 months, with favorable safety and tolerability profiles across all PD-L1 levels.